{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir%2FRilpivirine&page=2", "query": { "intervention": "Cabotegravir/Rilpivirine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir%2FRilpivirine&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir%2FRilpivirine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T15:08:01.326Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04973254", "title": "Improving Treatment and Retention Adherence in Nontraditional Settings", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB-RPV LA", "type": "OTHER" }, { "name": "Standard treatment within an HIV clinic", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-02-23", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973254" }, { "nct_id": "NCT05660980", "title": "Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Once daily CAB tablet + RPV tablet", "type": "DRUG" }, { "name": "Long acting CAB injectable + long acting RPV injectable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 90, "start_date": "2024-01-24", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Memphis, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660980" }, { "nct_id": "NCT07637942", "title": "Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV -1 Infection" ], "interventions": [ { "name": "Every 4-week long-acting injectable cabotegravir and rilpivirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2026-10-15", "completion_date": "2028-03-22", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 10, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07637942" }, { "nct_id": "NCT07682961", "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "Cabotegravir", "type": "DRUG" }, { "name": "Rilpivirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-07-14", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 16, "location_summary": "San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07682961" }, { "nct_id": "NCT01641809", "title": "Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1265744 10 mg", "type": "DRUG" }, { "name": "GSK1265744 30 mg", "type": "DRUG" }, { "name": "GSK1265744 60 mg", "type": "DRUG" }, { "name": "Efavirenz 600 mg", "type": "DRUG" }, { "name": "Rilpivirine 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2012-08-06", "completion_date": "2019-01-15", "has_results": true, "last_update_posted_date": "2020-01-30", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641809" }, { "nct_id": "NCT04001803", "title": "Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA+RPV LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-07-08", "completion_date": "2022-03-18", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 9, "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001803" }, { "nct_id": "NCT03639311", "title": "Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA", "type": "DRUG" }, { "name": "RPV LA", "type": "DRUG" }, { "name": "RPV", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2018-09-24", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639311" }, { "nct_id": "NCT06694805", "title": "A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA + RPV LA", "type": "DRUG" }, { "name": "Oral ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 326, "start_date": "2024-12-02", "completion_date": "2028-06-09", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06694805" }, { "nct_id": "NCT05096949", "title": "Implementing Cabenuva in Arkansas HIV Programs", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV-1-infection", "Medication Adherence", "Satisfaction, Patient" ], "interventions": [ { "name": "Home visit delivery strategy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-03-07", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096949" }, { "nct_id": "NCT04542070", "title": "A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Cabotegravir Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Rilpivirine Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "BIKTARVY Tablets (BIK)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2020-11-09", "completion_date": "2023-04-17", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-03T15:08:01.326Z", "location_count": 41, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04542070" } ] }